Citeline Podcasts

In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app.

Stories discussed in this episode:

MindMaze, ‘A Ratio Of Luke Skywalker And R2-D2’, Navigates The DTx Galaxy

Click Therapeutics Anticipates Pharma Will Begin Developing Digital Drugs From Clinical Stage

Sinaptica On Precision Neuromodulation To Combat Alzheimer’s: ‘No Drug Dares Go After Moderate Patients’

DHCoE-AI-Lifecycle-Management-Plan-To-Serve-As-Playbook-For-Standards

Hello Heart Says Update To Cardiovascular Health Tracker Could Benefit Women Especially

Interest in the human gut microbiome and the influence it exerts on a person’s wellbeing, from cognitive health to immunity, has been rapidly increasing in recent years. In this episode of HBW Insight's Over the Counter podcast we speak to Dublin-based food company Kerry Group about a particularly exciting, emerging area of microbiome-based wellness, postbiotics, which are defined by the International Scientific Association of Probiotics and Prebiotics (ISAPP) as a “preparation of inanimate microorganisms and/or their components that confers a health benefit on the host.” Given that postbiotics rely on inanimate ingredients, rather than live cultures as in yoghurts, they, may provide more suitable vehicles for consumer health innovation, suggests Kerry Group’s RDA senior manager of immune and joint health, Sonja Nodland. Nodland also explains what kinds of postbiotics are currently on the European market, for example for digestive and skin health and immunity, and the regulatory challenges that postbiotics share with other microbiome products in the region, such as pre- and pro-biotics.

Timestamps:

2:20 Introductions

4:00 What are postbiotics?

8:30 Advantages of postbiotics for consumer health innovation

10:20 Health benefits of postbiotics

12:00 Types of postbiotics

15:20 Kerry’s postbiotic portfolio

19:00 Postbiotic regulation in the European Union

28:00 Where to start with postbiotic innovation

Audio roundup of selected biopharma industry content from Scrip over the business week ended 23 August 2024. In this episode: CMS’s price reveal better than expected?; new diabetes risk data for Zepbound; can J&J’s lung cancer combo stand up to Tagrisso?; new recruits for BioMarin leadership; and Glenmark’s shifting revenues.

https://scrip.citeline.com/SC150795/Quick-Listen-Scrips-Five-MustKnow-Things

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Following the recent FDA rejection of MDMA therapy for PTSD, Emma and Flora discuss the future role of psychedelics in the treatment of mental health disorders. Content warning: This episode does contain mentions of sexual assault and abuse.

Apple Podcasts - https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836​

Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz​

TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/​

Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67​

Keith Murphy, co-founder of Organovo, discusses the growing potential of bioprinting and how the company is using its technologies to study and develop treatments for inflammatory bowel disease (IBD).

Audio roundup of selected biopharma industry content from Scrip over the business week ended 16 August 2024. In this episode: Merck & Co. steps into CD19 bispecific space; gene therapy patients rise, but slowly; Madrigal’s Rezdiffra plans; Korean biopharma financing recovering?; and approvals to watch out for in Q3.

https://scrip.citeline.com/SC150765/Quick-Listen-Scrips-Five-MustKnow-Things

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Pink Sheet reporter and editors discuss the take-aways from the landmark first Medicare negotiated drug prices and what additional information remains outstanding.

More On These Topics From The Pink Sheet

Medicare Negotiation Announcement: Discounts From List Price Up To 79%, But Net Savings Unclear: https://pink.citeline.com/PS155128/Medicare-Negotiation-Announcement-Discounts-From-List-Price-Up-To-79-But-Net-Savings-Unclear

Medicare Unveils Negotiated Prices, But Near-Term Opportunity To Learn From Process Is Limited: https://pink.citeline.com/PS155129/Medicare-Unveils-Negotiated-Prices-But-NearTerm-Opportunity-To-Learn-From-Process-Is-Limited

Round 1 Of US Drug Price Negotiations Suggests Medicare Can Beat Original Part D System: https://pink.citeline.com/PS155130/Round-1-Of-US-Drug-Price-Negotiations-Suggests-Medicare-Can-Beat-Original-Part-D-System

The Next 340B Battle: Discount Duplication With Medicare Negotiated Prices: https://pink.citeline.com/PS155043/The-Next-340B-Battle-Discount-Duplication-With-Medicare-Negotiated-Prices

世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。

今回取り上げた記事はこちら

What To Look Out For At ESC 2024

https://scrip.citeline.com/SC150740/What-To-Look-Out-For-At-ESC-2024

Compliance with environmental sustainability goals is no longer optional for medtech companies serving global healthcare markets. Thermo Fisher has made it a mission to be a leader in thought and actions in meeting Scope 1, 2 and 3 needs. Corporate VP and head of sustainability Meron Mathias explains the company's sustainability aims and methods, for itself and its customers, and stresses the importance of continuing to enhance patient care with innovative products at the same time.

Audio roundup of selected biopharma industry content from Scrip over the business week ended 9 August 2024. In this episode: Amgen positions for obesity and diabetes; BMS returns TIGIT asset in pipeline reshuffle; is Kerendia the next jewel in Bayer’s crown?; Japan pharma firms cut jobs; and Sun Pharma seeks GLP-1 partner.

https://scrip.citeline.com/SC150739/Quick-Listen-Scrips-Five-MustKnow-Things

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things